Prevention and management of co-morbidities in SLE

Tanmayee Bichile, Michelle Petri

Research output: Contribution to journalArticle

Abstract

The prognosis and survival of patients with systemic lupus erythematosus (SLE) have improved over the past few decades. The major cause of death is no longer active lupus, but instead cardiovascular disease, complications of renal failure, and malignancy. Co-morbid factors, including both traditional and non-traditional cardiovascular risk factors, can be targeted according to accepted guidelines. We will emphasize the deleterious effect of corticosteroids in contributing to cardiovascular risk and the need to shift maintenance prednisone doses to a much lower threshold.

Original languageEnglish (US)
JournalPresse Medicale
Volume43
Issue number6P2
DOIs
StatePublished - 2014

Fingerprint

Prednisone
Systemic Lupus Erythematosus
Renal Insufficiency
Cause of Death
Adrenal Cortex Hormones
Cardiovascular Diseases
Maintenance
Guidelines
Morbidity
Survival
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Prevention and management of co-morbidities in SLE. / Bichile, Tanmayee; Petri, Michelle.

In: Presse Medicale, Vol. 43, No. 6P2, 2014.

Research output: Contribution to journalArticle

@article{d7abd755b25b42d58dd5263a32b3814e,
title = "Prevention and management of co-morbidities in SLE",
abstract = "The prognosis and survival of patients with systemic lupus erythematosus (SLE) have improved over the past few decades. The major cause of death is no longer active lupus, but instead cardiovascular disease, complications of renal failure, and malignancy. Co-morbid factors, including both traditional and non-traditional cardiovascular risk factors, can be targeted according to accepted guidelines. We will emphasize the deleterious effect of corticosteroids in contributing to cardiovascular risk and the need to shift maintenance prednisone doses to a much lower threshold.",
author = "Tanmayee Bichile and Michelle Petri",
year = "2014",
doi = "10.1016/j.lpm.2014.03.009",
language = "English (US)",
volume = "43",
journal = "Presse Medicale",
issn = "0755-4982",
publisher = "Elsevier Masson",
number = "6P2",

}

TY - JOUR

T1 - Prevention and management of co-morbidities in SLE

AU - Bichile, Tanmayee

AU - Petri, Michelle

PY - 2014

Y1 - 2014

N2 - The prognosis and survival of patients with systemic lupus erythematosus (SLE) have improved over the past few decades. The major cause of death is no longer active lupus, but instead cardiovascular disease, complications of renal failure, and malignancy. Co-morbid factors, including both traditional and non-traditional cardiovascular risk factors, can be targeted according to accepted guidelines. We will emphasize the deleterious effect of corticosteroids in contributing to cardiovascular risk and the need to shift maintenance prednisone doses to a much lower threshold.

AB - The prognosis and survival of patients with systemic lupus erythematosus (SLE) have improved over the past few decades. The major cause of death is no longer active lupus, but instead cardiovascular disease, complications of renal failure, and malignancy. Co-morbid factors, including both traditional and non-traditional cardiovascular risk factors, can be targeted according to accepted guidelines. We will emphasize the deleterious effect of corticosteroids in contributing to cardiovascular risk and the need to shift maintenance prednisone doses to a much lower threshold.

UR - http://www.scopus.com/inward/record.url?scp=84902553318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902553318&partnerID=8YFLogxK

U2 - 10.1016/j.lpm.2014.03.009

DO - 10.1016/j.lpm.2014.03.009

M3 - Article

C2 - 24855047

AN - SCOPUS:84902553318

VL - 43

JO - Presse Medicale

JF - Presse Medicale

SN - 0755-4982

IS - 6P2

ER -